


Ivy Foundation


Largest Phase 0 Trials Program for Glioblastoma Patients in the United States

PRINCIPAL INVESTIGATORS



David Brachman, MD, FASTRO
Chief of Neuro-Radiation Oncology

Nader Sanai, MD, FAANS, FACS
Director, Division of Neurosurgical Oncology
Director, Barrow Brain Tumor Research Center



Lynn Ashby, MD
Chief of Neuro-Oncology

OBJECTIVES

- Identify first-in-class chemotherapies to target the genetic underpinnings of glioblastoma brain tumors.
- Personalize the drug-selection process for each individual glioblastoma patient through validated pharmacodynamics and rapid interrogation of biomarker assays for drug effect.
- Study the efficacy with which experimental drugs are able to penetrate human glioblastomas.
- Partner with pharmaceutical companies to recognize promising new chemotherapy agents and expedite their progress towards large-scale clinical trials.

PROGRESS REPORT

- Completed the first Phase 0 trial for recurrent glioblastoma patients in the United States. Patient accrual was achieved within 6 months, highlighting our capacity for accelerated study completion.
- Identified a new first-in-class targeted inhibitor with previously unknown glioblastoma tumor penetration features.
- Partnered with several multinational pharmaceutical companies to identify and develop new first-in-class chemotherapies for glioblastoma patients. The BNI Phase 0 portfolio currently includes 4 first-in-class targeted inhibitors for glioblastoma.
- Initiated the first Phase 0/II trial for glioblastoma patients in the United States. Targeted for completion in 2016.



— THE BEN AND CATHERINE —
IVY FOUNDATION